Guoyee Partner Accelerates L606 Clinical Trial, Doubling Investment

Guoyee Pharmaceutical's partner, Liquidia, is significantly increasing investment to expedite the global Phase 3 clinical trial for L606, named Re-Spire. The company announced during its second-quarter earnings call that the trial's enrollment is accelerating.

In the second quarter alone, Liquidia invested approximately $10.8 million in the Re-Spire project, nearly doubling the investment from the first quarter. This quarterly expenditure surpassed the total investment made in the first half of the previous year. Liquidia projects that its overall research and development expenses for the second half of 2026 will be roughly double that of the first half, with further increases planned for 2027. This indicates that the clinical development of L606 is entering a phase of substantial financial commitment.

Liquidia has positioned L606 as potentially the best-tolerated treprostinil formulation available. Unlike current inhaled products that require multiple daily doses, L606 offers a twice-daily dosing regimen. Roger Jeffs, the CEO, stated that no other product in clinical development has demonstrated the same range of dosage, tolerability, and duration as L606. He expressed high confidence in the ongoing global Phase 3 Re-Spire trial.

“

Liquidia has positioned L606 as 'potentially the best-tolerated treprostinil formulation to date.'

The company also noted that the effectiveness of inhaled prostacyclin treatments is closely linked to patients achieving adequate therapeutic doses. However, side effects like coughing have historically limited patients' ability to increase dosage and adhere to long-term treatment. Results from the 48-week Phase 3 open-label trial of L606 showed that over 90% of patients achieved actual medication doses higher than those targeted by current commercial inhaled therapies, demonstrating L606's favorable tolerability and dose-achievement capabilities.

Liquidia plans to advance three clinical trials for L606 concurrently. These include the ongoing US open-label study, the global Phase 3 Re-Spire trial for pulmonary hypertension with interstitial lung disease (PH-ILD), and the TRECOR trial for pulmonary arterial hypertension (PAH), which is slated to begin in the first half of 2027. Guoyee Pharmaceutical, which developed L606 as its proprietary liposomal long-acting inhaled formulation, is collaborating with Liquidia for its clinical development and commercialization. The company emphasized that L606 is entering a critical phase of value validation as Liquidia increases investment and advances multiple clinical trials.

“

Currently, we have not seen any other products in clinical development that can achieve the dose range, tolerability, and duration that L606 is currently demonstrating.